Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 19, 2021 06:00 ET | Source: AKAMPION

T-knife Announces Appointment of Thomas M. Soloway as Chief Executive Officer and Camille A. Landis as Chief Business Officer & Chief Financial Officer

San Francisco, CA / Berlin, Germany – January 19, 2021 — T-knife GmbH, a next-generation adoptive T-cell therapy company leveraging its proprietary humanized T-cell receptor (HuTCR) mouse platform to...
November 12, 2020 03:05 ET | Source: AKAMPION

Cardior Pharmaceuticals gibt positive Phase Ib Ergebnisse von CDR132L bei Herzinsuffizienz bekannt

Erste Substanz aus neuer Wirkstoffklasse zeigt ausgezeichnete Verträglichkeit und SicherheitEinzigartiger Wirkmechanismus bei Herzinsuffizienz durch Herzfunktionsdaten und Biomarker bestätigtPhase II...
November 12, 2020 03:05 ET | Source: AKAMPION

Cardior Pharmaceuticals Announces Positive Phase Ib Results of its Lead Compound CDR132L in Heart Failure

First-in-class compound showed excellent tolerability and safety Unique mode of action in chronic heart failure confirmed by data on cardiac function and biomarkersPhase II studies in subacute and...
September 21, 2020 04:00 ET | Source: AKAMPION

T-knife and Catalent Sign Technology Transfer and Manufacturing Agreement for Autologous T-Cell Receptor-Based Cell Therapy

BERLIN, GERMANY, and SOMERSET, N.J. – September 21, 2020 — T-knife GmbH, a next-generation adoptive T-cell company using its proprietary humanized T-cell receptor (HuTCR) mouse platform to treat solid...
August 06, 2020 04:00 ET | Source: AKAMPION

T-knife schließt Serie A Finanzierungsrunde über EUR 66 Millionen zur Entwicklung neuartiger T-Zell-Therapeutika ab

T-Zellrezeptoren auf Basis von T-knifes geschützter humanisierter Mausplattform (HuTCR) sollen überlegene Affinität und Spezifität bieten Versant Ventures und RA Capital Management Hauptinvestoren der...
August 06, 2020 04:00 ET | Source: AKAMPION

T-knife Completes EUR 66 Million Series A Financing to Develop Next-Generation T-Cell Therapies

T-knife’s proprietary humanized mouse platform (HuTCR) T-cell receptors expected to provide superior affinity/specificity properties Series A round led by Versant Ventures and RA Capital Management,...
December 16, 2019 03:55 ET | Source: AKAMPION

Aleva Neurotherapeutics Receives CE Mark for its directSTIM™ Deep Brain Stimulation System and Raises USD 8 Million Private Equity

Lausanne, Switzerland, December 16, 2019 – Aleva Neurotherapeutics, a leading developer of implants for deep brain stimulation (DBS) in major neurological indications such as Parkinson’s disease and...